Goal
Alternative treatment of cancer by normalising somatids and restoring immune function.
Problem
Cancer (tumour development and progression).
Concept Summary
714X is an injectable (and nebulisable) mixture containing camphor, ammonium salts, nitrates, sodium chloride, ethanol, water and nitrogen. It is claimed to fluidify lymph, deliver nitrogen to cancer cells, neutralise a purported tumour-derived factor (CKF) and unblock the immune system, thereby restoring normal somatid cycles and inhibiting cancer growth.
Detailed Description
The product is administered daily by intralymphatic injection into a groin lymph node for 21 days per cycle (typically three cycles). A secondary nasal administration using a nebuliser is optional for lung/oral cancers. The formulation lists camphor as the vehicle, ammonium salts to improve lymph circulation, and nitrogen as the active ingredient. The inventor also developed a "somatoscope" microscope to observe microscopic particles (somatids) in blood, which he claimed are involved in disease. No peer-reviewed clinical data support the efficacy; regulatory bodies have investigated the product.
Principles
- Nitrogen delivery to lymphatic system
- Camphor affinity for cancer cells
- Ammonium salts enhance lymph circulation
- Neutralisation of tumour-derived CKF factor
- Fluidification of lymph to unblock immune response
Scientific Domains
Materials
- Camphor
- Ammonium chloride
- Nitrate
- Sodium chloride
- Ethanol
- Water
- Nitrogen
- Aluminum (trace)
- Antimony (trace)
- Arsenic (trace)
- Barium (trace)
- Bore (trace)
- Cadmium (trace)
- Calcium (trace)
- Chromium (trace)
- Cobalt (trace)
- Copper (trace)
- Iron (trace)
- Lead (trace)
- Magnesium (trace)
Mechanisms of Action
- Fluidify lymphatic fluid
- Transport nitrogen to cancerous cells
- Neutralise CKF (cocancerogenic K factor)
- Unblock dysfunctional immune system
- Restore normal somatid life-cycle
Applications
- Alternative cancer therapy
- Immune system support
Claimed Performance
Reported to fluidify lymph, deliver nitrogen to cancer cells, neutralise CKF, unblock immune system and halt toxic secretions; side effects described as minimal, primarily burning sensation at injection site.
Experimental Evidence
"There have been few published animal studies of the safety and effectiveness of 714-X, and those that have been conducted have shown no beneficial effect." (Kaegi)
Limitations
- No peer-reviewed clinical data supporting efficacy
- Regulatory investigation by Health Canada and FDA
- Complex daily intralymphatic administration
- Potential camphor toxicity when taken internally
Red Flags
- Unproven efficacy and lack of reproducible data
- Regulatory scrutiny and investigation
- Claims contradict mainstream cancer biology
- Potential toxicity of camphor and trace metals
